EPCORE DLBCL-2: A phase 3 trial looking at the medication epcoritamab in people with DLBCL

This trial aims to assess the effectiveness of epcoritamab when given with intravenous (IV) or oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vinicristine and prednisone (R-CHOP) in people with diffuse large B-cell lymphoma (DLBCL).

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT05578976 

Trial aim and background 

The aim of this trial is to assess the effectiveness of epcoritamab when combined with R-CHOP in people with DLBCL.

People in the trial will either receive epcoritamab alongside R-CHOP followed by epcoritamab, or R-CHOP alone followed by rituximab.

The participants in the trial will be newly diagnosed with DLBCL and not have received any previous treatment. Participants will be randomly allocated to a group.

Epcoritamab is given subcutaneously and is a bispecific antibody, which is a new class of immunotherapy drug. Bispecific antibodies work by attaching to two targets, one on the surface of lymphoma cells and one on the surface of T cells (part of the immune system).  

Who can enter

Adults with newly diagnosed DLBCL who are planned to receive 6 cycles of R-CHOP may be eligible for this trial.

Locations

Recruitment is taking place at the following UK locations:

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham
  • Imperial College London, London
  • Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at:  https://www.clinicaltrials.gov/study/NCT05578976

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.